GenBioPro v. Raynes et al.

Docket No.
23-2194
Appellate Court
Fourth Circuit

Goal

  • Reverse the district court's dismissal of the case

Litigation Content

Why this Matters:

The Plaintiff alleges that West Virginia’s abortion ban, which effectively bans the sale of mifepristone in the state, conflicts with the Food and Drug Administration’s (FDA’s) federal approval of the drug. Ensuring that individuals have access to FDA-approved medication abortions enables patients to receive necessary reproductive health care.

Potential Impact:

Overriding the FDA’s expertise and preventing individuals from accessing effective medication for abortion services will jeopardize their health and safety.